PressOctober 27, 2022 Delic Labs President and CSO Dr. Markus Roggen to Discuss the Importance of R&D for Business Growth at MJBizCon
BlogOctober 26, 2022 Silo Pharma to Discuss Mainstream Pharma and Psychedelics at Wonderland Miami Conference
BlogOctober 25, 2022 What are Some of the Most Common Misconceptions About Psychedelics?: Mindshifting Moments #15
PressOctober 25, 2022 Silo Pharma – Distinctive with Ground-Breaking Research, Commitment to Developing Innovative Solutions
PressOctober 25, 2022 IntelGenx Receives FDA GDUFA Date for Xiromed-Partnered Development Candidate, Buprenorphine Buccal Film
PressOctober 25, 2022 atai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression
PressOctober 24, 2022 Reunion Neuroscience Appoints Chief Financial Officer and Vice President, Medical Affairs
PressOctober 24, 2022 Beckley Psytech Strengthens Pipeline and Development Team With Acquisition of Eleusis Therapeutics Limited
PressOctober 24, 2022 Algernon Pharmaceuticals Enters into a Clinical Trial Agreement with Yale University for a DMT Phase 2 Depression Study
PressOctober 20, 2022 Albert Labs Files New International PCT Patent Application for scalable API manufacturing
PressOctober 20, 2022 Silo Wellness Announces LOI for Potentially Largest Psilocybin Retreat Center in Oregon and the World – If November’s Election Is Favorable; and an Oregon Real Estate Law and Psilocybin Industry Primer
Market ResearchOctober 20, 2022 Death and Psychedelics: End of Life Applications for Mind-Altering Compounds
